Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.56 |
| ▸ | HPGD | P15428 | 3/20 | 0.56 |
| ▸ | GLA | P06280 | 2/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | ACHE | P22303 | 1/20 | 0.56 |
| ▸ | NQO2 | P16083 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.42 |
| ▸ | GAA | P10253 | 3/20 | 0.42 |
| ▸ | HTR3A | P46098 | 1/20 | 0.42 |
| ▸ | STAT3 | P40763 | 1/20 | 0.42 |
| ▸ | PDE2A | O00408 | 1/20 | 0.41 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.41 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | PTBP1 | P26599 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30511098 | 1.00 | TDP1 (0.63) | TDP1ALDH1A1HPGDGLAMAPT | |
| SCHEMBL4868283 | 0.88 | TDP1 (0.52) | TDP1ALDH1A1HPGDGLAMAPT | |
| SCHEMBL31413219 | 0.77 | ALDH1A1 (0.52) | TDP1ALDH1A1HPGDGLAMAPT | |
| SCHEMBL16535036 | 0.77 | TDP1 (0.59) | TDP1ALDH1A1HPGDGLAMAPT | |
| SCHEMBL30917310 | 0.77 | KMT2A (0.55) | TDP1ALDH1A1HPGDGLAMAPT | |
| SCHEMBL4161475 | 0.77 | TDP1 (1.00) | TDP1ALDH1A1HPGDGLAMAPT | |
| SCHEMBL358560 | 0.77 | TDP1 (0.59) | TDP1ALDH1A1HPGDGLAMAPT | |
| SCHEMBL1981418 | 0.77 | TLR8 (0.53) | TDP1ALDH1A1HPGDGLAMAPT | |
| SCHEMBL8400543 | 0.77 | ALDH1A1 (0.52) | TDP1ALDH1A1HPGDGLAMAPT | |
| SCHEMBL6849143 | 0.77 | ALDH1A1 (0.59) | TDP1ALDH1A1HPGDGLAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 90 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3114099-B1 | LOW-TOXICITY SMOKE PYROTECHNIC COMPOSITIONS FOR WIDE BAND MASKING | ETIENNE LACROIX TOUS ARTIFICES S A (FR) | 2021-05-26 | — | — | EP | claimed |
| CN-110041905-B | Fluorescent and phosphorescent dual luminescent material with switching effect and preparation method thereof | 华中科技大学 | 2020-05-19 | — | — | CN | claimed |
| CN-103923102-B | Synthesis method of compound 5, 8-di (3, 4-ethylenedioxy-thienyl) -quinoline | 南京工业大学 | 2017-04-05 | — | — | CN | claimed |
| EP-3114099-A1 | LOW-TOXICITY SMOKE PYROTECHNIC COMPOSITIONS FOR WIDE BAND MASKING | ETIENNE LACROIX TOUS ARTIFICES S.A. (FR) | 2017-01-11 | — | — | EP | claimed |
| WO-2015132266-A1 | LOW-TOXICITY SMOKE PYROTECHNIC COMPOSITIONS FOR WIDE BAND MASKING | ETIENNE LACROIX TOUS ARTIFICES S.A. (FR) | 2015-09-11 | — | — | WO | claimed |
| CN-103923102-A | Synthesis method of compound 5, 8-di (3, 4-ethylenedioxy-thienyl) -quinoline | NANJING UNIVERSITY OF TECHNOLOGY | 2014-07-16 | — | — | CN | claimed |
| US-20250388543-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-12-25 | — | — | US | disclosed |
| US-12503439-B2 | Heteroaryl compounds for the treatment of pain | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-12-23 | — | — | US | disclosed |
| EP-4511116-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN | Vertex Pharmaceuticals Incorporated (US) | 2025-02-26 | — | — | EP | disclosed |
| EP-4511115-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN | Vertex Pharmaceuticals Incorporated (US) | 2025-02-26 | — | — | EP | disclosed |
| US-20250002779-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | UNIVERSAL DISPLAY CORPORATION (US) | 2025-01-02 | — | — | US | disclosed |
| EP-3737657-B1 | USE OF A HALOGENATED SALT OF TETRAPHENYLPHOSPHONIUM AS A SMOKE-PRODUCING AGENT AND SMOKE-PRODUCING PYROTECHNIC COMPOSITION INCORPORATING SUCH MATERIAL | MECAR SA (BE) | 2024-02-07 | — | — | EP | disclosed |
| US-20240002345-A1 | HETEROCYCLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME, MANUFACTURING METHOD THEREFOR, AND COMPOSITION FOR ORGANIC LAYER | LT MATERIALS CO., LTD. (KR) | 2024-01-04 | — | — | US | disclosed |
| CN-1777628-A | Polyquinoline copolymer and organic electroluminescent device using same | HITACHI CHEMICAL CO LTD (JP) | 2006-05-24 | — | — | CN | disclosed |
| WO-2005049546-A1 | HALOGENATED BISDIARYLAMINOPOLYCYLIC AROMATIC COMPOUNDS AND POLYMERS THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2005-06-02 | — | — | WO | disclosed |
| US-20050075478-A1 | Method for producing polymerized hydrocarbon | JFE CHEMICAL CORPORATION (JP) | 2005-04-07 | — | — | US | disclosed |
| EP-1520846-A1 | Method for producing polymerized hydrocarbon | JFE Chemical Corporation (JP) | 2005-04-06 | — | — | EP | disclosed |
| EP-1373199-A4 | SPIRO-CYCLIC BETA-AMINO ACID DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES AND TNF-ALPHA CONVERTING ENZYME (TAGE) | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2004-04-07 | — | — | EP | disclosed |
| EP-1373199-A2 | SPIRO-CYCLIC BETA-AMINO ACID DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES AND TNF-ALPHA CONVERTING ENZYME (TAGE) | Bristol-Myers Squibb Pharma Company (US) | 2004-01-02 | — | — | EP | disclosed |
| WO-2002074738-A2 | SPIRO-CYCLIC BETA-AMINO ACID DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES AND TNF-ALPHA CONVERTING ENZYME (TAGE) | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-09-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250388543-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN | SCN8A, SCN1B, SCN3A | TDP1 2797/4885ALDH1A1 2279/4885HPGD 2534/4885 |
| US-12503439-B2 | Heteroaryl compounds for the treatment of pain | TRPV1, SCN3A, KCNN3 | TDP1 3607/4885ALDH1A1 1762/4885HPGD 546/4885 |
| US-20240002345-A1 | HETEROCYCLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME, MANUFACTURING METHOD THEREFOR, AND COMPOSITION FOR ORGANIC LAYER | CYP1B1, CYP4F11, NOTUM | TDP1 1390/4885ALDH1A1 80/4885HPGD 576/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.